Return to homepagePandemic Pact

The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the course of acute respiratory distress syndrome in COVID-19 patients

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Known Financial Commitments (USD)

    $533,600

  • Funder

    Novo Nordisk Foundation

  • Research Location

    Denmark

  • Lead Research Institution

    Gentofte Hospital

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Many of the most severely affected COVID-19 patients suffer from hypertension and/or diabetes. A majority of them take antihypertensive drugs that inhibit the renin-angiotensin system (RAS). Through a randomized clinical trial and using Danish registers and databases as well as patient records, this project will determine whether it will be beneficial to continue or stop treating COVID-19 patients in need of hospitalization with RAS inhibitors.